Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Basmisanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 19/20 | 0.98 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.98 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.98 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.98 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.98 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Basmisanil SCHEMBL2685527 | 0.99 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL15064759 | 0.94 | GABRA5 (0.89) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL20775357 | 0.93 | GABRA5 (0.89) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20775333 | 0.92 | GABRA5 (0.87) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL14896646 | 0.92 | GABRA5 (0.87) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2959565 | 0.90 | GABRA5 (0.84) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2960083 | 0.90 | GABRA5 (0.85) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4155478 | 0.90 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4162143 | 0.89 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2685021 | 0.89 | GABRA5 (0.81) | GABRA5GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975397-B2 | Solid forms | HOFFMANN-LA ROCHE INC. (US) | 2015-03-10 | — | — | US | claimed |
| US-20140329806-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2014-11-06 | — | — | US | claimed |
| US-20130172329-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | claimed |
| EP-2768821-B1 | SOLID FORMS OF (1,1-DIOXO-4-THIOMORPHOLINYL)-[6-[[3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-8975397-B2 | Solid forms | HOFFMANN-LA ROCHE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140329806-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2792360-A1 | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV | IP Gesellschaft für Management mbH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8785435-B2 | Solid forms | HOFFMANN-LA ROCHE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130172329-A1 | NOVEL SOLID FORMS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172329-A1 | NOVEL SOLID FORMS | F12, SLC10A1, CYP2F1 | GABRA5 3197/4885GABRA1 3294/4885GABRG2 3630/4885 |
| US-20140329806-A1 | NOVEL SOLID FORMS | F12, SLC10A1, CYP2F1 | GABRA5 3197/4885GABRA1 3294/4885GABRG2 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.